ストックスクリーナーアプリを入手
687.80
0.91%
6.22
アフターアワーズ：
687.80
Regeneron Pharmaceuticals Inc (REGN) 最新ニュース
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Regeneron Pharmaceuticals, Inc. of Class Action Lawsuit and Upcoming DeadlinesREGN - PR Newswire
REGENERON EXPANDS PRESENCE IN CANADA BY OPENING ITS FIRST HEADQUARTERS TO BETTER SERVE NEEDS OF CANADIANS WITH SERIOUS DISEASES - Quantisnow
Faruqi & Faruqi Reminds Regeneron Pharmaceuticals Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of March 10, 2025REGN - StreetInsider.com
Clear Harbor Asset Management LLC Buys 3,006 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat
Lmcg Investments LLC Trims Stock Holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat
REGN INVESTOR DEADLINE: Regeneron Pharmaceuticals, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit - PR Newswire
Levi & Korsinsky Reminds Regeneron Pharmaceuticals, Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of March 10, 2025 - Victoria Advocate
404 Shares in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Purchased by Mechanics Bank Trust Department - MarketBeat
MassMutual Private Wealth & Trust FSB Reduces Position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat
REGN INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Regeneron Pharmaceuticals, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit - PR Newswire
Regeneron Pharmaceuticals (REGN) Faces Securities Class - GlobeNewswire
Regeneron Pharmaceuticals (REGN) Faces Securities Class Action After Losing $9 Billion Value Following Q3 2024 Earnings Report – Hagens Berman - GlobeNewswire Inc.
REGN Investors Have Opportunity to Lead Regeneron Pharmaceuticals, Inc. Securities Fraud Lawsuit with the Schall Law Firm - PR Newswire
Cove Private Wealth LLC Buys New Position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat
REGN Investors Have Opportunity to Lead Regeneron Pharmaceuticals, Inc. Securities Fraud Lawsuit - Longview News-Journal
2025-01-20 | REGN INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Regeneron Therapeutics, Inc. Investors Have Opportunity to Lead Class Action Lawsuit! | NDAQ:REGN | Press Release - Stockhouse Publishing
Regeneron Pharmaceuticals, Inc. Class Action: The Gross Law Firm - GuruFocus.com
Regeneron Pharmaceuticals, Inc. Class Action: The Gross Law Firm Reminds Regeneron Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of March 10, 2025REGN - PR Newswire
ROSEN, A RANKED AND LEADING FIRM, Encourages Regeneron Pharmaceuticals, Inc. Investors to - The Bakersfield Californian
ROSEN, A RANKED AND LEADING FIRM, Encourages Regeneron - GlobeNewswire
Moss Adams Wealth Advisors LLC Buys 923 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat
Monarch Capital Management Inc. Acquires 549 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat
Jim Cramer on Regeneron Pharmaceuticals, Inc. (REGN): ‘This Company Has Never Lost Its Ability To Develop New Medicines’ - Insider Monkey
AdvisorNet Financial Inc Lowers Position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - Defense World
REGN INVESTOR ALERT: Robbins Geller Rudman & Dowd LLP - GlobeNewswire
B & T Capital Management DBA Alpha Capital Management Grows Position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Shares Sold by Boston Common Asset Management LLC - MarketBeat
Avanza Fonder AB Makes New $7.41 Million Investment in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat
SHAREHOLDER ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Regeneron Pharmaceuticals - StreetInsider.com
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Shares Sold by Procyon Advisors LLC - MarketBeat
ROSEN, LEADING INVESTOR COUNSEL, Encourages Regeneron - GlobeNewswire
Robbins LLP Urges REGN Stockholders with Large Losses to - GlobeNewswire
Regeneron Pharmaceuticals Inc. stock underperforms Friday when compared to competitors - MarketWatch
Woodstock Corp Trims Stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat
Regeneron Pharmaceuticals, Inc. (REGN) Investors Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit - Kilgore News Herald
Shareholders of Regeneron Pharmaceuticals, Inc. Should Contact L - GuruFocus.com
2025-01-17 | REGN SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Regeneron Therapeutics, Inc. Shareholders with Losses Have Opportunity to Lead Class Action Lawsuit! | NDAQ:REGN | Press Release - Stockhouse Publishing
Shareholders of Regeneron Pharmaceuticals, Inc. Should Contact Levi & Korsinsky Before March 10, 2025 to Discuss Your RightsREGN - Morningstar
Outlook Wealth Advisors LLC Invests $305,000 in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat
What to Expect From Regeneron Pharmaceuticals' Q4 2024 Earnings Report - Nasdaq
Fifth Third Wealth Advisors LLC Has $783,000 Stock Position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat
The Zacks Analyst Blog Moderna, Regeneron, Intellia Sage and GSK - Yahoo Finance
UBS Downgrades Regeneron Pharmaceuticals (REGN) - MSN
What to Expect From Regeneron Pharmaceuticals's Q4 2024 Earnings Report - MSN
DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Regeneron Pharmaceuticals - Stockhouse Publishing
Regeneron Pharmaceuticals Inc. stock underperforms Thursday when compared to competitors - MarketWatch
Regeneron Executives Sued for Medicare Overbilling, Stock Drop - Bloomberg Law
Regeneron Pharmaceuticals, Inc. Securities Fraud Class - GlobeNewswire
UBS cuts rating on Regeneron stock amid Eylea uncertainty - Investing.com
What To Expect From Regeneron Pharmaceuticals' Q4 2024 Earnings Report - Barchart
Pharma giant Regeneron is spending $119.5M on the world’s largest, most diverse genetic database using DNA from patient volunteers - AOL
$100 Invested In This Stock 15 Years Ago Would Be Worth This Much Today - Benzinga
REGN INVESTOR NOTICE: Regeneron Pharmaceuticals, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit – Company AnnouncementFT.com - Financial Times
Regeneron Pharmaceuticals (NASDAQ:REGN) Stock Rating Lowered by UBS Group - MarketBeat
Connective Portfolio Management LLC Has $449,000 Stock Position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat
The Gross Law Firm Reminds Regeneron Pharmaceuticals, Inc. Inves - GuruFocus.com
The Gross Law Firm Reminds Regeneron Pharmaceuticals, Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of March 10, 2025REGN - PR Newswire
1.40%
大文字化:
|
ボリューム (24 時間):